ecancer is developing a new accredited e-learning module designed to help reduce the risk of cancer patients developing osteonecrosis of the jaw (ONJ).
To help us develop the module we are asking oncology specialists like yourself to complete a short (five minute) survey.
Responses from the survey will help us assess levels of understanding of ONJ in the EU, Switzerland and Norway and the current treatment recommendations for the use of bone targeting agents or BTAs. This includes the RANK ligand inhibitor denosumab▼ 120mg [trade name XGEVA®], or bisphosphonates zoledronic acid [Zometa®] and pamidronic acid [Aredia®] and generics indicated for prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.
The e-learning module will be made available on an open access basis later this year and completion will count towards your continued professional development.
This learning activity is being given unrestricted support by Amgen (Europe) GmbH to measure and improve knowledge of the statements related to ONJ as described in the European Medicine Agency’s summary of product characteristics for bone-targeting agents. By participating in this survey you are granting ecancer permission to share your responses with Amgen.
Please note: Denosumab is subject to additional monitoring. All suspected adverse reactions should be reported.
EUHQ-NP-162x-0516-031025 - 5/2016